2,4-Diaminopyrimidine Derivatives for ALK2-Mediated Hepcidin Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for anemia of chronic disease (ACD) and certain cancers, such as breast and prostate cancer with bone metastasis, are inadequate due to the activation of the BMP signaling pathway leading to elevated hepcidin levels and iron storage, making iron intake ineffective and promoting tumor growth.
Innovation Solution
Development of 2,4-diaminopyrimidine derivatives and their pharmaceutically acceptable salts, hydrates, or stereoisomers that inhibit ALK2 kinase, thereby blocking BMP signaling and reducing hepcidin production, thus addressing the underlying cause of ACD and inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If iron intake is increased to treat anemia of chronic disease, then iron availability for red blood cell production should improve, but iron is stored in macrophages and cannot be utilized due to elevated hepcidin levels
Solution Approach 1:
The patent extracts and blocks the harmful BMP signaling pathway that causes pathological hepcidin production. By using ALK2/ALK3 inhibitors, the treatment specifically targets and removes the defective regulatory mechanism, allowing iron to be released from macrophage storage without being trapped by elevated hepcidin levels.
Solution Approach 2:
The patent changes the regulatory parameter of hepcidin production by inhibiting BMP signaling through ALK2/ALK3 blockade. This parameter change reduces pathological hepcidin levels, thereby altering the iron metabolism state from iron-trapped to iron-releasable, enabling effective iron utilization for red blood cell production.
2Quantity of substance
If BMP signaling is activated to regulate iron metabolism, then hepcidin production is controlled, but iron storage increases and iron-deficient red blood cells are produced
Solution Approach 1:
The patent introduces ALK2/ALK3 inhibitors as intermediary substances that mediate between BMP ligands and hepcidin production. These inhibitors block the signaling pathway at the receptor level, preventing the transmission of the BMP signal that would otherwise cause excessive hepcidin production and iron storage, thereby restoring normal iron distribution.
3Quantity of substance
If BMP signaling pathway is active in tumor cells, then tumor growth is regulated, but bone metastasis is promoted in breast and prostate cancer
Solution Approach 1:
The patent extracts and blocks the harmful BMP signaling activity in tumor cells that promotes bone metastasis. By using ALK2/ALK3 inhibitors, the treatment specifically removes the defective BMP signaling pathway in metastatic tumors, preventing the promotion of bone metastasis while allowing normal BMP signaling to continue in healthy tissues.
Data Source
AI summary
The present invention relates to a 2,4-diaminopyrimidine derivative, pharmaceutically acceptable salts thereof, hydrates, solvates or stereoisomers, and a preparation method thereof and an application of the compound used separately or in combination with other drugs in treating diseases having ALK2 kinase-mediated pathological features